Coronary Heart Disease and Hypertension as Late Effects of Testicular Cancer Treatment – a Minireview

Authors: M. Valentová 1,2;  B. Mladosievičová 1
Authors‘ workplace: Oddelenie klinickej patofyziológie LF UK v Bratislave, Slovenská republika 1;  I. interná klinika LF UK v Bratislave, Slovenská republika 2
Published in: Klin Onkol 2011; 24(1): 18-22
Category: Reviews


The modern treatment of testicular cancer has led to notable improvement in the prognosis of these patients. A significant number of testicular cancer survivors suffer from late effects of their treatment that can occur several years after the treatment. Cardiovascular late effects represent one of the most serious effects with respect to their life-threatening potential. Considering the higher risk of coronary heart disease, numerous studies have investigated the prevalence of cardiovascular risk factors in patients treated for testicular cancer. Higher prevalence of hypertension in patients after treatment for testicular cancer may be one of the reasons for their serious cardiovascular morbidity and mortality. The aim of this is to summarize the current knowledge on the impact of review treatment modalities used in testicular cancer therapy on prevalence of hypertension and its pathogenetic context. Both chemotherapy and radiotherapy are associated with increased prevalence of hypertension several years after completing the treatment. In patients treated with chemotherapy, hypertension is associated with administration of cisplatin. Regular and long-term monitoring of cardiovascular risk should be introduced to ensure better quality of life in these patients.

Key words:
testicular cancer – late effects – cardiotoxicity – coronary heart disease – hypertension – endothelial dysfunction


1. Horner MJ, Ries LAG, Krapcho M et al. SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD., based on November 2008 SEER data submission, posted to the SEER web site, 2009.

2. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8(9): 784–796.

3. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003; 170(1): 5–11.

4. Moger TA, Aalen OO, Heimdal K et al. Analysis of testicular cancer data using a frailty model with familial dependence. Stat Med 2004; 23(4): 617–632.

5. Safaei Diba Ch, Pleško I. Cancer incidence in the Slovak Republic 2004. National Cancer Registry of the Slovak Republic. Bratislava: National Health Information Center 2008: 168.

6. Ondrusova M, Ondrus D. Epidemiological features of testicular cancer in the Slovak Republic – retrospective study. Klin Onkol 2009; 22(2): 52–57.

7. Ondrušová M, Ondruš D. Nádory testis: Epidemiológia, etiológia, patológia a diagnostika. Urol List 2006; 4(3): 17–21.

8. Ondrusova M, Ondrus D, Dusek L et al. Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer. Neoplasma 2009; 56(6): 473–479.

9. Strumberg D, Brugge S, Korn MW et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for nonseminomatous testicular cancer. Ann Oncol 2002; 13(2): 229–236.

10. Kollmannsberger C, Kuzcyk M, Mayer F et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999; 17(4): 275–281.

11. Travis LB, Beard C, Allan J M et al. Testicular Cancer Survivorship: Research Strategies and Recommendations. J Natl Cancer Inst 2010; 102(15): 1–17.

12. van den Belt-Dusebout AW, de Wit R, Gietema JA et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25(28): 4370–4378.

13. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18(8): 1725–1732.

14. van den Belt-Dusebout AW, Nuver J, de Wit R et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24(3): 467–475.

15. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21(8): 1513–1523.

16. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk in long-term testicular cancer survivors. J Clin Oncol 2010; 28 (Suppl): abstr. 4533.

17. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53(3): 497–513.

18. Sagstuen H, Aass N, Fosså SD et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23(22): 4980–4990.

19. Boyer M, Raghavan D, Harris PJ et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8(1): 21–26.

20. Oh JH, Baum DD, Pham S et al. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol 2007; 24(2): 175–181.

21. Haugnes HS, Aass N, Fosså SD et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18(2): 241–248.

22. Nord C, Fosså SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 2003; 88(1): 36–41.

23. Wilson PW, D’Agnostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837–1847.

24. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002; 360(9349): 1903–1913.

25. Gietema JA, Sleijfer DT, Willemse PH et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 16(9): 709–715.

26. Hansen SW, Groth S, Daugaard G et al. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988; 6(11): 1728–1731.

27. Bissett D, Kunkeler L, Zwanenburg L et al. Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 1990; 62(4): 655–659.

28. Stoter G, Koopman A, Vendrik CP et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989; 7(8): 1099–1104.

29. Bokemeyer C, Berger CC, Kuczyk MA et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14(11): 2923–2932.

30. Petersen PM, Hansen SW. The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Ann Oncol 1999; 10(12): 1475–1483.

31. Fosså SD, Aass N, Winderen M et al. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 2002; 13(2): 222–228.

32. Daugaard G, Rossing N, Rørth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 1988; 21(2): 163–167.

33. Thompson SW, Davis LE, Kornfeld M et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 1984; 54(7): 1269–1275.

34. Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastin, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989; 7(10): 1457–1461.

35. Higa GM, Wise TC, Crowell EB. Severe, disabling neurologic toxicity following cisplatin retreatment. Ann Pharmacother 1995; 29(2): 134–137.

36. Bokemeyer C, Berger CC, Hartmann JT et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77(8): 1355–1362.

37. Travis LB, Fosså SD, Schonfeld SJ et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97(18): 1354–1365.

38. Poirier MC, Reed E, Litterst CL et al. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Re 1992; 52(1): 149–153.

39. Tothill P, Klys HS, Matheson LM et al. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 1992; 28A(8–9): 1358–1361.

40. Gietema JA, Meinardi MT, Messerschmidt J et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 355(9209): 1075–1076.

41. Gerl A, Schierl R. Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol 2000; 39(4): 519–522.

42. Brouwers EE, Huitema AD, Beijnen JH et al. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008; 8: 7.

43. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 1980; 208(4440): 198–200.

44. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56(12): 2765–2770.

45. Barbagallo M, Dominguez LJ, Galioto A et al. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med 2003; 24(1-3): 39–52.

46. Shi Y, Inoue S, Shinozaki R et al. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn J Cancer Res 1998; 89(7): 757–767.

47. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110(6): 835–842.

48. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001; 12(12): 2683–2690.

49. Nuver J, Smit AJ, Sleijfer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40(5): 701–706.

50. Nuver J, Smit AJ, van der Meer J et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23(36): 9130–9137.

51. Wethal T, Kjekshus J, Røislien J et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv 2007; 1(1): 8–16.

52. Vaughn DJ, Palmer SC, Carver JR et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112(9): 1949–1953.

53. Dewit L, Anninga JK, Hoefnagel CA et al. Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys 1990; 19(4): 977–983.

54. Helgadottir A, Thorleifsson G, Magnusson KP et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008; 40(2): 217–224.

55. McPherson R, Pertsemlidis A, Kavaslar N et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007; 316(5830): 1488–1491.

56. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447(7145): 661–678.

57. Samani NJ, Erdmann J, Hall AS et al. WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357(5): 443–453.

58. Mladosievičová B, Foltinová A. Genetické polymorfizmy – perspektívy predikcie toxicity cytostatík. In: Mladosievičová B, Kaiserová E, Foltinová A (eds). Možné neskoré následky protinádorovej liečby v detstve. 1. vyd. Bratislava: SAP 2007: 157–158.

59. Oldenburg J, Kraggerud SM, Brydøy M et al. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007; 5(70): 70.

60. Oldenburg J, Kraggerud SM, Cvancarova M et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25(6): 708–714.

61. Nuver J, Lutke Holzik MF, van Zweeden M et al. Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genomics 2005; 15(6): 399–405.

62. Riedemann L, Lanvers C, Deuster D et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 2008; 8(1): 23–28.

Paediatric clinical oncology Surgery Clinical oncology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account